MedTrace Logo

A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes

NCT00401583 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-11-13

No results posted yet for this study

Summary

This is a Phase I study to determine the effect of GW786034 (pazopanib) on P450 enzymes. This study will help determine which types of drugs may interact with GW786034.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

GW786034 (pazopanib)

Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.

DRUG

Probe drugs

probe drugs will be oral midazolam (3 mg), warfarin (10 mg), omeprazole (40 mg), caffeine (200 mg), and dextromethorphan (30 mg).

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-28
Primary Completion
2008-02-20
Completion
2008-02-20

Countries

  • United States
  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00401583 on ClinicalTrials.gov